Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Neoadjuvant Chemotherapy for HR+/HER2- Breast Cancer
NCT06611813Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in breast cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Pathologic Complete Response at 2 years and Residual Cancer Burden 0-1 Ratio at 2 years. Started Jun 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06611813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611813.